News

VolitionRx Limited Reports Robust Q3 2025 Growth and Updates

VolitionRx Limited Reports Robust Q3 2025 Growth and Updates

VolitionRx Limited Reports Financial Results for Q3 2025

VolitionRx Limited (NYSE AMERICAN: VNRX), a pioneering epigenetics firm, has revealed its financial results and significant business developments for the third quarter of 2025. The company's leadership will host a conference call to discuss these results in detail, providing insights into the company's future direction.

Update on Collaboration Agreements

Cameron Reynolds, President and Group CEO, shared exciting news about recent commercial advancements. In its commitment to push forward with the Nu.Q® platform for human diagnostics, VolitionRx secured two prominent agreements this quarter. Notable collaborations include a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome (APS) with Werfen, and a Co-Marketing and Services Agreement with Hologic, both industry leaders in their respective fields.

Expanding Global Partnerships

VolitionRx is actively engaging with approximately 10 leading diagnostic firms around the globe. These discussions are at various stages of due diligence and technological transfer, including evaluating clinical samples and negotiating contract terms. The company is optimistic about securing additional human licensing agreements, with updates expected as these negotiations develop.

Clinical Evidence and Future Publications

The emerging clinical evidence supporting the application of the Nu.Q® technology in cancer and sepsis detection is promising. The management anticipates several peer-reviewed publications in the near future that will validate their groundbreaking Capture-Seq™ technology, which aims to enhance cancer detection methods significantly.

Financial Performance Overview

In the third quarter, the company reported revenue of $0.6 million, demonstrating a commendable 32% growth compared to the previous year. Operational expenses also saw a reduction, down by 10% year-on-year. Moreover, the net loss has decreased by 8%, indicating improved financial health.

Investment and Liquidity Position

VolitionRx reported net cash used in operating activities for the quarter at $3.6 million, reflecting a 33% improvement from the previous year. Following the quarter's conclusion, the company received approximately $6.1 million from a public offering, enhancing its financial resources for future initiatives.

Upcoming Conference Call Details

VolitionRx will host a conference call on November 14, 2025, at 8:30 a.m. U.S. Eastern Time. Louise Batchelor, Chief Marketing and Communications Officer, along with other key executives, will provide updates on essential events and milestones achieved during the quarter.

About VolitionRx Limited

VolitionRx is committed to transforming the landscape of disease detection through its innovative approach to epigenetics. The company is focused on developing efficient, cost-effective blood tests aiming for earlier detection of diseases, including various cancers associated with NETosis, thus improving patient outcomes. Their research and development operations are primarily based in Belgium, alongside facilities in the U.S. and London.

Future Directions and Innovations

With a dedicated innovation laboratory and a diverse portfolio of diagnostic tests, VolitionRx is advancing its mission to not only save lives but also enhance the quality of life for patients through early detection and continual monitoring of diseases. The company aims to replicate its success in the veterinary diagnostics market within the human diagnostics sector.

Frequently Asked Questions

What financial results did VolitionRx report for Q3 2025?

VolitionRx reported a revenue of $0.6 million for Q3 2025, with a 32% increase year-on-year.

What new agreements has VolitionRx established recently?

The company signed agreements with Werfen and Hologic, enhancing its commercial strategies in human diagnostics.

What are the expectations for future publications from VolitionRx?

VolitionRx anticipates several peer-reviewed publications that will include clinical evidence supporting their technology and innovations.

How does VolitionRx plan to develop further in diagnostics?

They are focused on securing additional licensing agreements and expanding partnerships within the diagnostics market.

What is the mission of VolitionRx?

VolitionRx aims to save lives through early detection of diseases and continuous monitoring, leveraging its epigenetics focus.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cut Winter Heating Costs with Townsend's Rebate Help

Updated Category News Views 6

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
Timur Turlov Leads FIDE with Chess and Digital Focus

Updated Category News Views 5

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Continue Reading
Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Updated Category News Views 3

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Continue Reading
Endurance Energy's Modular Tech Revs Up Southeast Asia

Updated Category News Views 4

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 9

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 4

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading
AST SpaceMobile Faces Class Action Over Misstatements

Updated Category News Views 4

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Continue Reading
Farm Aid 2026: A Resilient Tribute to Family Farmers

Updated Category News Views 4

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Continue Reading
China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 4

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading

Top 5 Most Recently Viewed Articles

Hainan's Ambitious Plans for the Future of Global Trade

Updated Category News Views 252

Hainan's Bold Steps Towards Global Trade Leadership Hainan's Free Trade Port (Hainan FTP) is reaching a pivotal moment with independent customs operations slated for implementation. This significant milestone is a central goal within the Master Plan for Building the Hainan Free Trade Port, representing both a fundamental achievement and a symbol of Hainan's evolving role...

Continue Reading
Constellation Energy Corporation Announces Quarterly Dividend

Updated Category News Views 222

Constellation Energy Declares Quarterly Dividend The Board of Directors of Constellation Energy Corporation (Nasdaq: CEG) has recently made an important announcement regarding its financial health and commitment to its shareholders. They declared a quarterly dividend of $0.3525 per share on the company’s common stock. This dividend is to be paid to shareholders who are...

Continue Reading
Pure Ice Cream Expands Production Capacity Significantly

Updated Category News Views 97

Pure Ice Cream Expands Production Capacity Significantly Pure Ice Cream, famed for its popular brands like Kwality Ice Creams and Hershey's Ice Cream, has announced an important agreement that will enhance its production capabilities. This agreement involves a substantial investment of AED 80 million to establish a new manufacturing facility at Dubai Industrial City,...

Continue Reading
Alto Neuroscience Faces Class Action Lawsuit Amid Concerns

Updated Category News Views 119

Understanding the Class Action Against Alto Neuroscience Alto Neuroscience, Inc. is currently facing a shareholder class action lawsuit that has drawn significant attention. This legal action arises from allegations that the company issued false and misleading statements regarding its product, ALTO-100, specifically related to its effectiveness in treating major...

Continue Reading
Comparative Analysis of Meta Platforms with Industry Rivals

Updated Category News Views 868

Understanding Meta Platforms and Its Market Position In today's fast-paced business environment, a detailed examination of companies like Meta Platforms (NASDAQ: META) is essential for investors and analysts alike. This article aims to provide a thorough comparative analysis of Meta alongside its key competitors within the Interactive Media & Services sector. By...

Continue Reading